Michael Ryskin

Stock Analyst

(n/a)
# 4,642
Out of 4,650 analysts
34
Total ratings
n/a
Success rate
n/a
Average return

Stocks Rated by Michael Ryskin

Tempus AI
Oct 2, 2024
Downgrades: Neutral
Price Target: $45$60
Current: $43.34
Upside: +38.44%
Guardant Health
Jul 18, 2024
Maintains: Buy
Price Target: $28$40
Current: $22.20
Upside: +80.18%
Alight
Jun 25, 2024
Maintains: Buy
Price Target: $10$9.5
Current: $7.18
Upside: +32.31%
Exscientia
Jan 5, 2024
Downgrades: Neutral
Price Target: $11$9
Current: $5.23
Upside: +72.08%
Maravai LifeSciences Holdings
Dec 12, 2023
Upgrades: Buy
Price Target: $10$8
Current: $7.21
Upside: +10.96%
Certara
Aug 15, 2023
Maintains: Buy
Price Target: $27$24
Current: $10.42
Upside: +130.33%
Avantor
Jul 31, 2023
Maintains: Buy
Price Target: $27$24
Current: $22.64
Upside: +6.01%
Align Technology
Apr 27, 2023
Maintains: Underperform
Price Target: $190$225
Current: $215.80
Upside: +4.26%
Zoetis
Nov 4, 2022
Maintains: Buy
Price Target: $225$180
Current: $182.76
Upside: -1.51%
Singular Genomics Systems
Aug 10, 2022
Downgrades: Underperform
Price Target: $90
Current: $13.32
Upside: +575.68%
Downgrades: Neutral
Price Target: $550$470
Current: $449.44
Upside: +4.57%
Downgrades: Neutral
Price Target: n/a
Current: $6.87
Upside: -
Downgrades: Neutral
Price Target: $80$52
Current: $18.37
Upside: +183.07%
Downgrades: Underperform
Price Target: $17$10
Current: $4.29
Upside: +133.10%